Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (DFPH) Receivables - Other (2020 - 2025)

Historic Receivables - Other for Oncology Institute (DFPH) over the last 6 years, with Q3 2025 value amounting to $339000.0.

  • Oncology Institute's Receivables - Other fell 530.73% to $339000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $339000.0, marking a year-over-year decrease of 530.73%. This contributed to the annual value of $346000.0 for FY2024, which is 3720.51% down from last year.
  • According to the latest figures from Q3 2025, Oncology Institute's Receivables - Other is $339000.0, which was down 530.73% from $276000.0 recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Receivables - Other ranged from a high of $1.3 million in Q1 2022 and a low of $276000.0 during Q2 2025
  • Moreover, its 5-year median value for Receivables - Other was $425000.0 (2022), whereas its average is $527437.5.
  • Its Receivables - Other has fluctuated over the past 5 years, first soared by 99469.03% in 2021, then tumbled by 6653.64% in 2023.
  • Oncology Institute's Receivables - Other (Quarter) stood at $1.2 million in 2021, then tumbled by 50.12% to $617000.0 in 2022, then fell by 10.7% to $551000.0 in 2023, then plummeted by 37.21% to $346000.0 in 2024, then dropped by 2.02% to $339000.0 in 2025.
  • Its last three reported values are $339000.0 in Q3 2025, $276000.0 for Q2 2025, and $346000.0 during Q1 2025.